On the receiving end—patient perception of the side-effects of cancer chemotherapy

Coates, Alan S.; Abraham, Suzanne; Kaye, Stanley B.; Sowerbutts, Timothy; Frewin, Cheryl; Fox, Richard M.; Tattersall, Martin H. N.

doi:10.1016/0277-5379(83)90418-2

Cited by 848 publications

(466 citation statements)

References 9 publications

Supporting

Mentioning

444

Contrasting

Unclassified

Order By: Relevance

“…Results of the search strategy and reasons for excluding articles In a population of mixed cancer patients where the majority had advanced cancer, three articles used the same methodology [16,22,30] to determine which chemotherapy side effects patients had experienced and their relative importance to the patient. Alopecia ranked 3rd in 1983 and 2nd in 2002 [16,30]. When data were reported in the subgroup of breast cancer patients, hair loss ranked 1st and 2nd in 1983 and 2002, respectively [16,30].…”

Section: Relative Importance Of Hair Loss Among Chemotherapy-related mentioning

confidence: 99%

“…Alopecia ranked 3rd in 1983 and 2nd in 2002 [16,30]. When data were reported in the subgroup of breast cancer patients, hair loss ranked 1st and 2nd in 1983 and 2002, respectively [16,30]. Alopecia ranked 2nd in breast and lung cancer, two cancer types with chemotherapyassociated alopecia as a side effect [30].…”

Section: Relative Importance Of Hair Loss Among Chemotherapy-related mentioning

confidence: 99%

See 1 more Smart Citation

Chemotherapy‐induced alopecia and effects on quality of life among women with breast cancer: a literature review

2007

View full text Add to dashboard Cite

Background: Alopecia is a common side effect of chemotherapies used in the treatment of breast cancer. The aim of this review is to describe the effects of alopecia on quality of life (QOL) in this population.Methods: We conducted a literature review using Medline, Embase, Cumulative Index to Nursing and Allied Health Literature and PsycInfo databases. We searched for studies on the effects of alopecia on various aspects of QOL in breast cancer patients including anxiety and distress, body image, sexuality, self‐esteem, social functioning, global QOL and return to work outcomes.Results: A total of 38 articles were included in the review. Hair loss consistently ranked amongst the most troublesome side effects, was described as distressing, and may affect the body image.Conclusions: We found very little quantitative data on other aspects of QOL. More research is needed to determine the presence and extent of negative effects on chemotherapy‐induced alopecia on various aspects of QOL. Copyright © 2007 John Wiley & Sons, Ltd.

show abstract

Section: Relative Importance Of Hair Loss Among Chemotherapy-related mentioning

confidence: 99%

Section: Relative Importance Of Hair Loss Among Chemotherapy-related mentioning

confidence: 99%

Chemotherapy‐induced alopecia and effects on quality of life among women with breast cancer: a literature review

2007

View full text Add to dashboard Cite

show abstract

“…Nausea and vomiting are the most distressing aspects of cancer chemotherapy (Coates et al, 1983). The prevention and treatment of these symptoms was greatly improved with the development of selective 5HT3-receptor antagonists, which control nausea and vomiting in more than 70% of cisplatin-treated patients in the first cycle of chemotherapy (Marty et al, 1990;de Mulder et al, 1990;Hainsworth et al, 1991).…”

mentioning

confidence: 99%

Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles

Wit

Berg²,

Burghouts³

et al. 1998

Br J Cancer

View full text Add to dashboard Cite

Initial high antimemetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles R de Wit', H van den Berg', J Burghouts2, J Nortier3, P Slee4, C Rodenburg5, J Keizer6, M Fonteyn7, J Verweij1 and J Wils7 Summary We have reported previously that the anti-emetic efficacy of single agent 5HT3 antagonists is not maintained when analysed with the measurement of cumulative probabilities. Presently, the most effective anti-emetic regimen is a combination of a 5HT3 antagonist plus dexamethasone. We, therefore, assessed the sustainment of efficacy of such a combination in 125 patients, scheduled to receive cisplatin 2 70 mg m-2 either alone or in combination with other cytotoxic drugs. Anti-emetic therapy was initiated with 10 mg of dexamethasone and 3 mg of granisetron intravenously, before cisplatin. On days 1-6, patients received 8 mg of dexamethasone and 1 mg of granisetron twice daily by oral administration. Protection was assessed during all cycles and calculated based on cumulative probability analyses using the method of Kaplan-Meier and a model for transitional probabilities. Irrespective of the type of analysis used, the anti-emetic efficacy of granisetron/dexamethasone decreased over cycles. The initial complete acute emesis protection rate of 66% decreased to 30% according to the method of Kaplan-Meier and to 39% using the model for transitional probabilities. For delayed emesis, the initial complete protection rate of 52% decreased to 21% (Kaplan-Meier) and to 43% (transitional probabilities). In addition, we observed that protection failure in the delayed emesis period adversely influenced the acute emesis protection in the next cycle. We conclude that the anti-emetic efficacy of a 5HT3 antagonist plus dexamethasone is not maintained over multiple cycles of highly emetogenic chemotherapy, and that the acute emesis protection is adversely influenced by protection failure in the delayed emesis phase.

show abstract

“…1,2 Twenty years ago, emesis was the number one scourge of chemotherapy. 3 This is no longer the case because of the widespread integration into clinical oncology practice of the 5-hydroxytryptamine-3 (5-HT 3 ) receptor antagonist class of antiemetics. Antiemetics include such drugs as ondansetron (Zofran, GlaxoSmithKline, Research Triangle Park, NC) and granisetron (Kytril, Roche Laboratories, Nutley, NJ).…”

mentioning

confidence: 99%

Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5‐hydroxytryptamine‐3 antiemetics

Hickok

Roscoe

Morrow

et al. 2003

Cancer

184

View full text Add to dashboard Cite

BACKGROUNDClinical reports suggest that nausea remains a side effect of chemotherapy despite widespread use of serotonin receptor antagonists. This study summarized the frequency, timing, and intensity of postchemotherapy nausea for patients receiving doxorubicin, cisplatin, or carboplatin.METHODSThree hundred sixty chemotherapy‐naïve patients (73% female) were enrolled in a study testing the ability of an information intervention to reduce nausea. Of these, 322 subjects completed the Morrow Assessment of Nausea and Emesis (MANE), as well as a 5‐day self‐report diary, at Cycle 1 (300 subjects completed the MANE and self‐report diary at Cycle 2). All patients received a 5‐hydroxytryptamine‐3 receptor antagonist (ondansetron) with dexamethasone on the day of treatment.RESULTSSeventy‐six percent of the patients developed nausea during the 5‐day period, beginning with the Cycle 1 infusion, and 73% of patients reported delayed nausea (DN) during Days 2–5. The proportions were similar during Cycle 2. Fifty‐five percent of patients described their DN as being of moderate or greater intensity compared with 28% of patients who described acute nausea. Carboplatin was less likely to cause DN than either of the other agents (56% of 106 patients compared with 75% of 47 receiving cisplatin and 83% of 169 taking doxorubicin). The mean peak DN severity was 4.34 (range, 1–7) for doxorubicin, which was significantly higher than the mean peak value for carboplatin (3.66) but was not significantly different from the mean peak value for cisplatin (4.26). Eighteen percent of patients did not experience nausea until Day 3 or later.CONCLUSIONSDespite prophylaxis with ondansetron, the majority of patients receiving one of these common chemotherapy agents experienced nausea. The frequency of DN was nearly twice that of acute nausea. Results show the need for continued development of antiemetics that are effective against DN. Cancer 2003;97:2880–6. © 2003 American Cancer Society.DOI 10.1002/cncr.11408

show abstract

On the receiving end—patient perception of the side-effects of cancer chemotherapy

Cited by 848 publications

References 9 publications

Chemotherapy‐induced alopecia and effects on quality of life among women with breast cancer: a literature review

Chemotherapy‐induced alopecia and effects on quality of life among women with breast cancer: a literature review

Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles

Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5‐hydroxytryptamine‐3 antiemetics

Contact Info

Product

Resources

About